BTIG initiated coverage of AnaptysBio with a Buy rating and $55 price target. The checkpoint agonism in autoimmune disease remains underexplored, and the company is pursuing this broad opportunity with PD-1 and BTLA agonists that are well-positioned to emerge as best-in-class, the analyst tells investors in a research note. While there have been safety questions with the approach given the success of checkpoint inhibitors in cancer historically, a closer look at the biology and preceding datasets leaves the firm persuaded that these concerns have been overstated, leaving a near-term opportunity for investors to get involved in the space, BTIG added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ANAB:
- Palo Alto Networks, Home Depot downgraded: Wall Street’s top analyst calls
- AnaptysBio initiated with a Buy at Stifel
- UPS upgraded, Nike downgraded: Wall Street’s top analyst calls
- AnaptysBio initiated with an Overweight at Piper Sandler
- Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference